Отчет об анализе размера, доли и тенденций мирового рынка лечения болезни Крона – обзор отрасли и прогноз до 2031 года

Анализ рынка по болезни Крона

Рынок болезни Крона переживает динамичный рост, обусловленный достижениями в терапевтических вариантах и ​​растущей распространенностью. Развитие рынка включает внедрение биологических препаратов и таргетной терапии, которые предлагают более эффективное управление заболеванием. Например, одобрение новых моноклональных антител, таких как Ведолизумаб и Устекинумаб, значительно улучшило результаты лечения пациентов за счет воздействия на определенные воспалительные пути. Кроме того, разрабатываемые препараты и текущие клинические испытания изучают новые подходы к лечению, такие как пероральные ингибиторы JAK и стратегии персонализированной медицины. На рынке также наблюдается рост инвестиций в исследования и разработки, при этом фармацевтические компании и биотехнологические фирмы сосредотачиваются на передовых методах лечения для решения неудовлетворенных потребностей. Ожидается, что этот растущий акцент на инновациях в сочетании с растущей осведомленностью и улучшенными методами диагностики будет продвигать рынок вперед, предлагая новую надежду пациентам и расширяя возможности лечения.

Размер рынка Болезни Крона

Объем мирового рынка борьбы с болезнью Крона в 2023 году оценивался в 9,85 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 13,17 млрд долларов США, при среднегодовом темпе роста в 3,70% в прогнозируемый период с 2024 по 2031 год. Помимо аналитических данных о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ перспективных направлений, анализ цен и нормативно-правовую базу.

Тенденции рынка лечения болезни Крона

« Растущее внимание к персонализированной медицине»

The Crohn’s disease market is evolving with several key trends shaping its landscape. One notable trend is the growing focus on personalized medicine, which tailors treatment plans based on individual patient profiles. For instance, recent advancements in genomic research have enabled the development of targeted therapies that address specific genetic mutations associated with Crohn's disease. Biologics such as anti-TNF agents and newer therapies such as Janus Kinase (JAK) inhibitors are being refined to provide more effective and individualized treatment options. This trend is driven by a need for treatments that offer better efficacy and fewer side effects compared to traditional therapies. Additionally, the rise of digital health technologies, including mobile apps for symptom tracking and telemedicine consultations, is improving patient management and adherence. These developments reflect a shift towards more precise and patient-centered approaches in the Crohn’s disease market, enhancing treatment outcomes and overall patient care.

Report Scope and Crohn’s Disease Market Segmentation     

Crohn’s Disease Market Definition

Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the digestive tract, which can occur anywhere from the mouth to the anus. It commonly affects the ileum (the last part of the small intestine) and the colon (the large intestine). The inflammation caused by Crohn's disease can lead to symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. The exact cause of Crohn's disease is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. The condition is marked by periods of flare-ups and remission, and while there is no cure, treatments are available to manage symptoms and improve quality of life.

Crohn’s Disease Market Dynamics

Drivers

• Increasing Prevalence of Crohn’s Disease

The increasing prevalence of Crohn’s disease is a significant driver of market growth, reflecting a rising global incidence of this chronic inflammatory condition. According to the Crohn's & Colitis Foundation, approximately 3 million individuals in the United States alone are affected by inflammatory bowel diseases, including Crohn’s disease. Such growing patient population underscores the urgent need for effective treatment options. As the number of diagnosed cases continues to climb, driven by factors such as improved diagnostic techniques and greater disease awareness, there is a corresponding surge in demand for innovative therapies. This heightened demand is prompting pharmaceutical companies and biotech firms to accelerate the development of new treatments, further fueling market expansion and improving the overall management of Crohn’s disease.

• Increasing Application of Stem Cells

The increasing application of stem cells in treating diseases is becoming a notable driver for the Crohn's disease market. Stem cell therapy presents new possibilities for managing and potentially curing Crohn's disease by fostering tissue repair and modulating immune responses. For instance, recent studies have investigated the use of mesenchymal stem cells (MSCs) for Crohn's disease, revealing that MSCs can diminish inflammation and facilitate healing in the gastrointestinal tract. The potential of stem cell therapy to target the root causes of the disease and improve treatment outcomes is fueling both interest and investment in this field. Such growing focus on stem cell research is contributing to the market's expansion and holds promise for advancing more effective strategies for managing Crohn's disease.

Opportunities

• Increasing Development of Advanced Imaging Techniques

The development and implementation of advanced imaging techniques, such as high-resolution magnetic resonance enterography (MRE) and capsule endoscopy, are significantly improving the accuracy and early detection of Crohn’s Disease. Additionally, the integration of novel biomarkers, such as fecal calprotectin levels and genetic markers, is enhancing diagnostic precision and differentiation from other inflammatory bowel diseases. Companies that innovate and offer these advanced diagnostic tools can tap into a growing market need for more effective early detection and monitoring solutions. By improving diagnostic capabilities, these initiatives not only facilitate earlier and more accurate diagnosis but also drive demand for targeted treatments, thereby expanding market opportunities for diagnostic and therapeutic solutions in the Crohn’s disease sector.

• Growing Awareness and Advocacy

Growing awareness and advocacy for Crohn’s disease play a crucial role in enhancing disease management and fostering proactive treatment approaches. Efforts by patient advocacy groups, such as the Crohn's & Colitis Foundation, have significantly raised public awareness and educated both patients and healthcare providers about the condition. For instance, “Take Steps” walk, an initiative by the Crohn's & Colitis Foundation, which raises millions of dollars annually to support research and patient services. Such advocacy efforts not only contribute to advancements in treatment but also improve patient access to emerging therapies and resources, thereby driving overall market growth and improving outcomes for those affected by Crohn’s disease.

Restraints/Challenges

• High Cost of Treatments

The high cost of treatments is a significant challenge in the Crohn's disease market, particularly with advanced therapies such as biologics and new targeted drugs. Medications such as Adalimumab and Ustekinumab, although effective, come with substantial price tags that can be prohibitive for many patients. High costs limits accessibility, especially for those in low-income or underinsured populations, who may find it difficult to afford these essential treatments. The financial burden extends beyond individual patients to healthcare systems, which face increased costs and budget constraints. Consequently, widespread adoption of these advanced therapies can be hindered, impacting overall market growth.

• High Cost of Advanced Crohn’s Disease

The high cost of advanced Crohn’s disease poses a significant challenge in the global market, particularly for products incorporating antimicrobial properties or cutting-edge materials. These advanced dressings, designed to enhance wound healing and prevent infections, often come with a higher price tag due to the sophisticated technologies and materials involved. For instance, antimicrobial dressings that contain silver or honey can be substantially more expensive than traditional options. Such elevated cost can limit accessibility, especially in low-resource settings where healthcare budgets are constrained and insurance coverage may be insufficient. Consequently, patients in economically disadvantaged regions or those without adequate insurance may face difficulties obtaining these advanced dressings, potentially impacting their treatment outcomes and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Crohn’s Disease Market Scope

The market is segmented on the basis of procedures, therapeutic type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Procedures

• Colonoscopy
• Flexible Sigmoidoscopy
• Computerized Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Capsule Endoscopy
• Double-Balloon Endoscopy
• Small Bowel Imaging

Therapeutic Type

• Non-surgical
• Surgical

End User

• Hospitals and Clinics
• Research Institutes
• Diagnostic Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Others

Crohn’s Disease Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, procedures, therapeutic type, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the Crohn's Disease market due to its advanced healthcare infrastructure, robust research and development capabilities of pharmaceutical companies, and swift adoption of cutting-edge healthcare technologies. The region's high prevalence of gastrointestinal disorders is also driving industry trends and market growth.

The Asia-Pacific region is expected to experience the highest growth rate during the forecast period, driven by increased investments in healthcare infrastructure and enhanced engagement of regulatory bodies in research and development activities. This growth is further supported by the expanding healthcare needs of a rapidly growing population and the region's ongoing efforts to modernize medical facilities and services.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Crohn’s Disease Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Crohn’s Disease Market Leaders Operating in the Market Are:

• GSK plc. (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Janssen Global Services, LLC (U.S.)
• UCB S.A. (Belgium)
• Ferring (Switzerland)
• Tillotts Pharma AG (Switzerland)
• Merck & Co., Inc. (США)
• Amgen Inc. (США)

Последние разработки на рынке лечения болезни Крона

• В апреле 2022 года Фонд Крона и Колита профинансировал Microbiotica в рамках своей Программы венчурных фондов по воспалительным заболеваниям кишечника. Финансирование поможет Microbiotica ускорить свои исследования и внести вклад в новые терапевтические решения для лечения болезни Крона и язвенного колита.
• В апреле 2022 года Engitix расширила свое партнерство с Takeda, сосредоточившись на открытии и разработке инновационных терапевтических средств для фибростенозных воспалительных заболеваний кишечника, таких как болезнь Крона. Это расширенное сотрудничество направлено на использование опыта Engitix в моделировании тканей и обширных возможностей терапевтических разработок Takeda для решения неудовлетворенных потребностей в лечении этих сложных состояний

SKU-36286